JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
Scope & Guideline
Unraveling the complexities of heart health and medication.
Introduction
Aims and Scopes
- Pharmacological Interventions for Cardiovascular Diseases:
The journal emphasizes studies on various pharmacological agents used to treat cardiovascular diseases, including novel therapies and existing medications, assessing their safety and efficacy. - Clinical Outcomes and Real-World Evidence:
Research that evaluates the outcomes of cardiovascular treatments in clinical practice, including observational studies and real-world data analyses, is a core focus. - Mechanistic Studies in Cardiovascular Pharmacology:
Investigations into the underlying mechanisms of action of cardiovascular drugs, including molecular and cellular pathways, are regularly featured. - Therapeutic Innovations and Trials:
The journal places a strong emphasis on clinical trials and innovative therapeutic approaches, including combination therapies and new drug formulations. - Impact of Comorbidities on Cardiovascular Treatment:
Research examining how comorbid conditions (e.g., diabetes, chronic kidney disease) affect cardiovascular treatment outcomes is a prominent theme.
Trending and Emerging
- SGLT2 Inhibitors and Heart Failure:
There is a growing focus on the role of SGLT2 inhibitors in treating heart failure, especially in patients with diabetes, highlighting their multifaceted benefits. - Personalized Medicine and Genotyping:
Emerging studies emphasize the importance of personalized medicine approaches, including genotyping for anticoagulant therapy, reflecting a trend towards individualized treatment strategies. - Impact of Lifestyle Factors on Cardiovascular Health:
Research exploring the effects of lifestyle factors—such as diet, physical activity, and smoking—on cardiovascular health and treatment outcomes is gaining traction. - Cardiovascular Effects of Novel Therapies:
An increased interest in the cardiovascular implications of non-cardiovascular drugs and therapies, including those used in cancer treatment, is evident in recent publications. - Integrative Approaches to Cardiovascular Care:
There is a notable trend towards integrative strategies combining pharmacological and non-pharmacological interventions, emphasizing holistic patient management.
Declining or Waning
- Traditional Antihypertensive Agents:
Research focusing solely on traditional antihypertensive medications has decreased, as newer agents and combination therapies are gaining prominence. - Static Observational Studies:
The prevalence of static observational studies without innovative designs or significant clinical implications appears to be declining, as the journal increasingly favors studies with robust methodologies and real-world applications. - Basic Science without Clinical Relevance:
Papers focusing solely on basic science aspects of cardiovascular pharmacology, lacking direct clinical relevance or application, have been published less frequently.
Similar Journals
Heart Views
Exploring the future of heart health through shared knowledge.Heart Views is a prestigious and influential journal dedicated to the field of cardiology and cardiovascular medicine, published by Wolters Kluwer Medknow Publications. With an Open Access model implemented since 2010, the journal ensures that its valuable research findings are accessible to a global audience, fostering knowledge dissemination and collaboration among researchers, professionals, and students alike. While the current impact factor is not specified, its commitment to quality and peer-reviewed content has established it as a significant resource within the cardiology community. The journal publishes a diverse array of articles, including original research, reviews, and clinical studies aimed at advancing the understanding and treatment of cardiovascular diseases. Heart Views serves as an essential platform for sharing innovative ideas and practices, thereby contributing to improved patient care and outcomes in the dynamic field of heart health.
Rational Pharmacotherapy in Cardiology
Enhancing Treatment Strategies with Cutting-Edge ResearchRational Pharmacotherapy in Cardiology, published by the SOC CARDIOLOGY RUSSIAN FEDERATION, stands as a crucial platform for advancing knowledge in the field of cardiology and pharmacology. Established as an Open Access journal in 2005, it allows for unrestricted access to research findings, fostering collaboration among researchers, clinicians, and students. The journal, with its ISSN 1819-6446 and E-ISSN 2225-3653, focuses on the intersection of rational pharmacotherapy and cardiovascular medicine, aiming to enhance treatment strategies and patient outcomes through evidence-based studies. Though currently positioned in the Q4 category in both cardiology and pharmacology rankings, its ongoing commitment to rigorous peer review and scholarly research ensures its relevance and growth in the scientific community. With a unique address in Moscow, Russia, the journal seeks to serve as a valuable resource for those dedicated to improving cardiovascular health and therapeutic practices worldwide, making it an essential read for professionals keen on the latest trends and discoveries in this vital area of medicine.
VASCULAR PHARMACOLOGY
Unlocking the mysteries of vascular biology and therapeutics.Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.
CARDIOVASCULAR RESEARCH
Pioneering discoveries in cardiology and physiology.CARDIOVASCULAR RESEARCH, published by Oxford University Press, is a premier academic journal dedicated to the evolving field of cardiology and cardiovascular medicine. With a remarkable impact factor reflecting its significant contribution to the scientific community, this journal maintains a Q1 ranking in both Cardiology and Physiology categories, demonstrating its commitment to publishing high-quality research that influences clinical practices and healthcare outcomes. Established in 1967, the journal has consistently provided a platform for innovative studies and reviews, aiming to advance our understanding of cardiovascular physiology and pathology. Researchers, professionals, and students will find published articles crucial for their work, as the journal covers a broad spectrum of topics including molecular biology, genetics, and clinical studies. While currently not offering open access options, CARDIOVASCULAR RESEARCH remains accessible through institutional and individual subscriptions, ensuring that the latest findings are available to those in the cardiovascular science community.
Cardiovascular Diagnosis and Therapy
Empowering Practitioners with Essential Cardiovascular KnowledgeCardiovascular Diagnosis and Therapy, an esteemed journal in the field of Cardiology and Cardiovascular Medicine, is published by AME PUBLISHING COMPANY, based in Hong Kong, China. With an ISSN of 2223-3652 and an E-ISSN of 2223-3660, this open-access journal aims to present cutting-edge research that significantly advances diagnostic and therapeutic practices in cardiovascular health. Recognized for its impact, it holds a 2023 category quartile ranking of Q2 and is positioned at rank #124 out of 387 in Scopus, reflecting its noteworthy contribution to medical literature with a percentile of 68th. The journal welcomes contributions that span various aspects of cardiovascular research, including clinical trials, epidemiological studies, and innovative therapeutic approaches, making it a vital resource for researchers, practitioners, and students alike, committed to improving cardiovascular care.
Nepalese Heart Journal
Illuminating the Path to Cardiovascular WellnessNepalese Heart Journal, published by the CARDIAC SOC NEPAL, serves as a premier platform for disseminating knowledge in the field of cardiology and cardiovascular health. With an ISSN of 2091-2978, this journal aims to bridge the gap between researchers, clinicians, and academicians by presenting high-quality, peer-reviewed articles that address clinical practices, innovative research, and emerging trends in heart disease management, especially within the context of Nepal and the surrounding region. Although it operates under a traditional publishing model, its commitment to excellence aids in reinforcing the scientific discourse in an area critical to public health. The journal is a valuable resource for professionals and students alike who are focused on advancing their understanding of cardiology and its implications for health policy and practice. Exploring the intersections of local challenges and global advancements in heart health, the Nepalese Heart Journal is poised to contribute meaningfully to the evolving landscape of cardiovascular research.
Journal of the Practice of Cardiovascular Sciences
Empowering Research, Transforming Cardiovascular PracticesJournal of the Practice of Cardiovascular Sciences, published by Wolters Kluwer Medknow Publications, is an esteemed Open Access journal dedicated to advancing knowledge in the field of cardiovascular health. With its ISSN 2395-5414 and E-ISSN 2454-2830, the journal serves as a vital platform for researchers, healthcare professionals, and students to disseminate and access high-quality studies, innovations, and practical applications related to cardiovascular sciences. Established in 2015 as an Open Access journal, it promotes widespread sharing of insights to enhance cardiovascular practices and address contemporary challenges in the field. As part of a reputable publishing group, the journal is poised for growth and impact, contributing significantly to the ongoing dialogue in cardiovascular research and clinical practice.
Cardiovascular Therapeutics
Pioneering Insights for a Healthier HeartCardiovascular Therapeutics is a renowned Open Access journal, published by WILEY-HINDAWI, that has been at the forefront of advancing knowledge in the field of cardiology and cardiovascular medicine since its establishment. With a strong commitment to disseminating high-quality research, the journal has successfully positioned itself within the Q2 quartile in multiple categories, including Cardiology and Cardiovascular Medicine, Medicine (miscellaneous), and Pharmacology. The journal is indexed in Scopus, achieving impressive rankings, such as #95 out of 387 in Cardiology, and #87 out of 272 in Medical Pharmacology. Situated in the United Kingdom, Cardiovascular Therapeutics embraces an Open Access model since 2019, ensuring that groundbreaking research is accessible to researchers, practitioners, and students across the globe. The journal is dedicated to publishing original research articles, reviews, and clinical studies that contribute to the understanding and treatment of cardiovascular diseases, making it an essential resource for those invested in improving patient outcomes and advancing therapeutic strategies in this vital area of medicine.
KIDNEY & BLOOD PRESSURE RESEARCH
Transforming Knowledge into Clinical Practice.Kidney & Blood Pressure Research, published by KARGER, is a premier open-access journal dedicated to the evolving fields of nephrology and cardiovascular medicine. Since its inception in 1978 and with a forward-looking scope extending to 2024, this journal plays a vital role in disseminating innovative research and clinical findings related to kidney health and blood pressure regulation. With an impressive 2023 Impact Factor and ranked in the second quartile (Q2) in both cardiology and nephrology categories, it is recognized as a significant resource among its peers, including a Scopus rank of #23 in Nephrology and #128 in Cardiology. The journal's commitment to open access since 2013 further ensures that cutting-edge research is readily available to the global scientific community. Based in Switzerland, the journal not only fosters academic collaboration but also addresses critical health challenges related to kidney function and hypertension. It is a crucial platform for researchers, healthcare professionals, and students alike, encouraging the ongoing dialogue and advancement of knowledge in these critical areas of health.
Minerva Cardiology and Angiology
Transforming cardiovascular practices with cutting-edge findings.Minerva Cardiology and Angiology, published by EDIZIONI MINERVA MEDICA, is a prominent journal in the field of cardiology and cardiovascular medicine, with an ISSN of 2724-5683 and E-ISSN of 2724-5772. Established in 2021, this journal aims to foster the dissemination of cutting-edge research, clinical practice guidelines, and innovative methodologies relevant to cardiovascular health. As of 2023, it holds a commendable Q3 quartile rank in its category, reflecting its growing influence within the scientific community. The journal is indexed in Scopus, where it ranks #221 out of 387 in its field, placing it in the 43rd percentile overall. Although it currently does not offer Open Access options, articles published in Minerva Cardiology and Angiology contribute significantly to ongoing discussions and advancements in heart and vascular health. The journal serves as an invaluable resource for researchers, healthcare professionals, and students seeking to stay informed on the latest developments in cardiology.